Table 2

Risk of neuropsychiatric adverse events associated with the use of montelukast at different time window periods (3, 7, 14, 28 and 56 days)

Time window period (days)No. of exposed in hazard period (n=161 386)
N (%)
No. of exposed in control period (n=645 544)
N (%)
CrudeAdjusted
OR (95% CI)*P valueOR (95% CI)†P value
39773(6.06)38 276(5.93)1.04(1.01 to 1.08)0.00901.28(1.24 to 1.32)<0.0001
712 673(7.85)48 882(7.57)1.07(1.04 to 1.09)<0.00011.29(1.26 to 1.33)<0.0001
1417 080(10.58)63 578(9.85)1.13(1.10 to 1.15)<0.00011.34(1.31 to 1.37)<0.0001
2824 568(15.22)87 991(13.63)1.20(1.18 to 1.22)<0.00011.38(1.36 to 1.41)<0.0001
5635 969(22.29)135 123(20.93)1.11(1.10 to 1.13)<0.00011.21(1.19 to 1.22)<0.0001
  • *Calculated by conditional logistic regression.

  • †Calculated by conditional logistic regression adjusted for concomitant medications.